Anti-coagulative and gastrointestinal motility regulative activities of Fructus Aurantii Immaturus and its effective fractions.

OBJECTIVE Fructus Aurantii Immaturus (FAI) has been used in the treatment of gastrointestinal disorders (GIDs) in traditional Chinese medicine (TCM) for thousands of years, which also has been found to have effects on cardiovascular diseases (CVDs) in recent years. The current study aimed at investigating the anti-coagulative and gastrointestinal motility regulative activities of different fractions isolated from FAI, which may have both effects on gastrointestinal and cardiovascular systems, in the manners of network pharmacology analysis and experiments in vivo and in vitro. METHODS We obtained water decoction, volatile oils, alkaloids and flavonoids from FAI, which were identified by gas chromatography-mass spectrometry (GC-MS) and high performance liquid chromatography (HPLC). Network pharmacological analysis was used to explore the relationship between the various types of chemical constituents, gene target and biological pathways of FAI. Then, the effective fractions in terms of anti-coagulative and gastrointestinal motility regulative activities were investigated by the experiment of rabbit intestinal smooth muscles contraction, mice small intestine propulsion rate and blood-clotting time, and verified by the blood stasis model. RESULTS From the Network pharmacological analysis, the flavonoids were predicted to be the main active ingredients on gastrointestinal and cardiovascular systems. Experimental results also showed that flavonoids could significantly increase the small intestine propulsion rate and extend the blood-clotting time of mice. The Flavonoids could alleviate the increased fractional shortening (FS), left ventricular outflow, hematocrit and fibrinogen, and ameliorate the pathological changes of myocardial tissues caused by blood stasis. CONCLUSION These findings indicated that flavonoids in FAI might be the main effective fractions on gastrointestinal motility and anti-coagulation.

[1]  Gui-biao Zhang,et al.  Network Pharmacology: A New Approach for Chinese Herbal Medicine Research , 2013, Evidence-based complementary and alternative medicine : eCAM.

[2]  Junliang Pan,et al.  Processing of Pro-atrial Natriuretic Peptide by Corin in Cardiac Myocytes* , 2002, The Journal of Biological Chemistry.

[3]  R. DuBois,et al.  Eicosanoids and the gastrointestinal tract. , 1995, Gastroenterology.

[4]  S. M. Kamruzzaman,et al.  Ginsenoside‐Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation , 2012, British journal of pharmacology.

[5]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition , 2001 .

[6]  A. Ochocka,et al.  Isozymes Delta of Phosphoinositide-specific Phospholipase C and Their Role in Signal Transduction in the Cell , 2022 .

[7]  A. Di Leo,et al.  Endothelial function and cardiovascular risk in active inflammatory bowel diseases. , 2013, Journal of Crohn's & colitis.

[8]  A. Di Leo,et al.  The association between cardiac and gastrointestinal disorders: causal or casual link? , 2016, Journal of cardiovascular medicine.

[9]  Peicai Li,et al.  Effect of Aurantii Fructus Immaturus Flavonoid on the Contraction of Isolated Gastric Smooth Muscle Strips in Rats , 2016, Evidence-based complementary and alternative medicine : eCAM.

[10]  J. Kinsella,et al.  Dietary n-3 polyunsaturated fatty acids and amelioration of cardiovascular disease: possible mechanisms. , 1990, The American journal of clinical nutrition.

[11]  S. Mody,et al.  Gastrointestinal comorbidities associated with atrial fibrillation , 2014, SpringerPlus.

[12]  P. Mannon,et al.  The fundamental basis of inflammatory bowel disease. , 2007, The Journal of clinical investigation.

[13]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[14]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[15]  Z. Yuan.  Influence of Fructus Aurantii Immaturus Flavonoids on Gastrointestinal Motility in Rats with Functional Dyspepsia , 2012 .

[16]  Shao Li,et al.  Traditional Chinese medicine network pharmacology: theory, methodology and application. , 2013, Chinese journal of natural medicines.

[17]  O. Poyrazoglu,et al.  Is Inflammatory Bowel Disease a Risk Factor for Early Atherosclerosis? , 2010, Angiology.

[18]  E. Kuipers,et al.  Patients with chronic gastrointestinal ischemia have a higher cardiovascular disease risk and mortality. , 2012, Atherosclerosis.

[19]  B. Marzouk,et al.  Characterization of Bioactive Compounds in Tunisian Bitter Orange (Citrus aurantium L.) Peel and Juice and Determination of Their Antioxidant Activities , 2013, BioMed research international.

[20]  P. Gama,et al.  MAPKs and Signal Transduction in the Control of Gastrointestinal Epithelial Cell Proliferation and Differentiation , 2013, International journal of molecular sciences.

[21]  Pei-gang Wang,et al.  Dietary total flavonoids intake and risk of mortality from all causes and cardiovascular disease in the general population: A systematic review and meta‐analysis of cohort studies , 2017, Molecular nutrition & food research.

[22]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[23]  S. Al-Rejaie,et al.  Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. , 2013, World journal of gastroenterology.

[24]  K. Park,et al.  Flavonoids identified from Korean Citrus aurantium L. inhibit Non-Small Cell Lung Cancer growth in vivo and in vitro , 2014 .

[25]  J. Castillo,et al.  Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. , 2008, Journal of agricultural and food chemistry.

[26]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[27]  J. Gálvez,et al.  Flavonoids in Inflammatory Bowel Disease: A Review , 2016, Nutrients.

[28]  Wenyuan Gao,et al.  Systematic Analysis of Main Constituents in Rat Biological Samples after Oral Administration of the Methanol Extract of Fructus Aurantii by HPLC-ESI-MS/MS , 2014, Iranian journal of pharmaceutical research : IJPR.

[29]  Xiangyang Wu,et al.  Da-Cheng-Qi-Tang Promotes the Recovery of Gastrointestinal Motility After Abdominal Surgery in Humans , 2007, Digestive Diseases and Sciences.

[30]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[31]  P. Chatzopoulou,et al.  Volatile Constituents and Antioxidant Activity of Peel, Flowers and Leaf Oils of Citrus aurantium L. Growing in Greece , 2013, Molecules.

[32]  J. Zhong.  Effect of Immature Bitter Orange on model rats of blood stasis in prethrombotic state , 2003 .

[33]  Andrew E Moran,et al.  Demographic and epidemiologic drivers of global cardiovascular mortality. , 2015, The New England journal of medicine.

[34]  H. El‐Serag.  Time trends of gastroesophageal reflux disease: a systematic review. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  M. E. Pinto,et al.  Flavonoids with Gastroprotective Activity , 2009, Molecules.

[36]  C. Hiruma-Lima,et al.  The effect of a minor constituent of essential oil from Citrus aurantium: the role of β-myrcene in preventing peptic ulcer disease. , 2014, Chemico-biological interactions.

[37]  D. Cheresh,et al.  Pathophysiological consequences of VEGF-induced vascular permeability , 2005, Nature.